OTCPK:YBAO

Stock Analysis Report

Executive Summary

YBCC, Inc. does not have significant operations.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • YBCC has significant price volatility in the past 3 months.
  • YBCC is not covered by any analysts.

Share Price & News

How has YBCC's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

YBAO

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-35.7%

YBAO

9.9%

US Medical Equipment

0.6%

US Market

YBAO underperformed the Medical Equipment industry which returned 9.5% over the past year.

YBAO underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

YBAOIndustryMarket
7 Day0%1.1%-0.6%
30 Day-25.0%0.6%2.2%
90 Dayn/a2.9%1.1%
1 Year-35.7%-35.7%10.8%9.9%2.9%0.6%
3 Year-77.9%-77.9%70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is YBCC's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is YBCC undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether YBCC is trading at an attractive price based on the cash flow it is expected to produce in the future. But as YBCC has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of YBAO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through YBCC regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is YBCC expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as YBCC has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of YBAO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access YBCC's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has YBCC performed over the past 5 years?

-13.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

YBCC does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare YBCC's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare YBCC's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

Whilst YBCC has efficiently used shareholders’ funds last year (Return on Equity greater than 20%), this is metric is skewed due to its high level of debt.


Return on Assets

It is difficult to establish if YBCC has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if YBCC improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is YBCC's financial position?


Financial Position Analysis

YBCC's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

YBCC has no long term commitments.


Debt to Equity History and Analysis

YBCC's level of debt (108.4%) compared to net worth is high (greater than 40%).

Unable to establish if YBCC's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 4.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

YBCC has less than a year of cash runway based on current free cash flow.

YBCC has less than a year of cash runway if free cash flow continues to grow at historical rates of 63.5% each year.


Next Steps

Dividend

What is YBCC's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate YBCC's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate YBCC's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as YBCC has not reported any payouts.

Unable to verify if YBCC's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as YBCC has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of YBCC's salary, the management and board of directors tenure and is there insider trading?

US$60k

CEO Compensation


CEO

Xiuhua Song (48yo)

3.1yrs

Tenure

US$60,000

Compensation

Mrs. Xiuhua Song has been Chief Executive Officer, Acting Chief Financial Officer and Director of YBCC, Inc. since August 2016 and also serves as its Secretary, Chairman and Treasurer. Mrs. Song has been t ...


CEO Compensation Analysis

Xiuhua's remuneration is lower than average for companies of similar size in United States of America.

Xiuhua's compensation has been consistent with company performance over the past year, both up more than 20%.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Xiuhua Song (48yo)

    Chairman

    • Tenure: 3.1yrs
    • Compensation: US$60.00k

Board Members

  • Xiuhua Song (48yo)

    Chairman

    • Tenure: 3.1yrs
    • Compensation: US$60.00k

Company Information

YBCC, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: YBCC, Inc.
  • Ticker: YBAO
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$606.345k
  • Shares outstanding: 7.85m
  • Website: https://www.ybccinc.com

Number of Employees


Location

  • YBCC, Inc.
  • 618 Brea Canyon Road
  • Suite A
  • Walnut
  • California
  • 91789
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
YBAOOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2016

Biography

YBCC, Inc. does not have significant operations. The company focuses on the acquisition of or merger with an existing company. Previously, it was engaged in the bio-science manufacture and research busines ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:56
End of Day Share Price2019/09/11 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.